Clinical trials: Dapagliflozin
Heart Failure
The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.
Heart failure (HF) is a chronic condition that is characterized by a weakened and enlarged heart. It typically causes symptoms such as breathlessness and swelling of the legs, and it is a serious illness that shortens life…
- Trial name
- TAPERED-HF (NCT07513883)
- Testing
- Down-titration, Continuation of guideline-directed heart failure therapy
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Ziekenhuis Oost-Limburg
Diabetes Mellitus, Type 2, Arterial Hypertension
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.
- Conditions
- Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes
- Trial name
- GliRACo1 (NCT03917758)
- Testing
- SGLT2 inhibitor
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Gestational Hypertension, Hypertension in Pregnancy
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum…
- Conditions
- Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia
- Trial name
- DAPA-HP (NCT06785116)
- Testing
- Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Michigan
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, CKD and Albuminuria
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and…
- Trial name
- NCT02547935
- Testing
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 26.
- Trial name
- EPIDOTE (NCT03499704)
- Testing
- Pioglitazone + Alogliptin, Alogliptin, Metformin
- Where
- 15 sites in South Korea
- Volunteers
- 133 people
- Sponsor
- Celltrion Pharm, Inc.
Myocardial Infarction, Acute Coronary Syndrome
Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes
Type 2 diabetes mellitus (T2DM) is one of the most important risk factors for atherosclerotic heart disease. Strategies focused solely on glycemic control have failed to demonstrate vascular events reduction in this population.
- Conditions
- Myocardial Infarction, Acute Coronary Syndrome, Diabetes, Ventricular Dysfunction
- Trial name
- NCT06286878
- Testing
- Dapagliflozin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo
Cardiorenal Syndrome
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic…
- Trial name
- SGLT2i in CRS (NCT06111768)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Type 2 Diabetes
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
- Trial name
- NCT05226897
- Testing
- YYC405-T, Metformin≥1000mg, Dapagliflozin 10mg
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Healthy
Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food.
- Trial name
- NCT01156246
- Testing
- Dapagliflozin/Metformin
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at…
- Trial name
- DERIVE (NCT02413398)
- Testing
- Dapagliflozin 10 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 321 people
- Sponsor
- AstraZeneca
Type2 Diabetes Mellitus, Stable Coronary Artery Disease
Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity
A Phase III, single-centre, randomized, 2-arm, parallel-group, double blind, placebo-controlled study, consisting of a screening phase (Days -14 to -1), a 4-week double-blind, placebo-controlled treatment phase and a 4-week…
- Trial name
- DapaHeart (NCT03313752)
- Testing
- Dapagliflozin 10Mg Tab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Giaccari Andrea
Acute Kidney Injury
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
To compare, by insulin use at the index date, the incidence of hospitalization for acute kidney injury (AKI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695082
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 539,310 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Evaluation of Dapagliflozin Taken Twice-daily
This study is being carried out to see if dapagliflozin - administered in a daily dose of 2.5 mg given twice a day or 5 mg twice a day or 10mg once daily - in addition to metformin, is beneficial in diabetes treatment, and if so…
- Trial name
- NCT01217892
- Testing
- dapagliflozin, metformin
- Where
- 55 sites in Germany, Hungary and 5 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Type II; Diabetes
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
- Trial name
- AZ11040 (NCT02984644)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Fontan Circulation, Single Ventricle Heart Disease
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT06762964
- Testing
- Dapagliflozin tablet
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Physical Activity
Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin.
- Trial name
- NCT02371187
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Christopher Bell
SGLT2 INHIBITORS, Lupus Nephritis
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
The goal of this Randomized, controlled trial in 100 patients with LN with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2.
- Conditions
- SGLT2 INHIBITORS, Lupus Nephritis, BMD
- Trial name
- NCT05704088
- Testing
- Dapagliflozin tablet
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Type 2 Diabetes
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01646320
- Testing
- Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
- Where
- 66 sites in United States, Czechia and 6 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone.
- Trial name
- NCT00528879
- Testing
- Dapagliflozin, Metformin
- Where
- 75 sites in United States, Argentina and 3 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca